BioInvent International AB (publ) (BINV.ST)
SEK 39.75
(2.45%)
SEK 39.75
(2.45%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 1.4 Billion SEK | -18.22% |
| 2022 | 1.71 Billion SEK | 18.3% |
| 2021 | 1.44 Billion SEK | 80.32% |
| 2020 | 802.64 Million SEK | 254.98% |
| 2019 | 226.11 Million SEK | 87.8% |
| 2018 | 120.4 Million SEK | -29.2% |
| 2017 | 170.04 Million SEK | -38.46% |
| 2016 | 276.29 Million SEK | 407.46% |
| 2015 | 54.44 Million SEK | -26.53% |
| 2014 | 74.1 Million SEK | -9.0% |
| 2013 | 81.43 Million SEK | -30.12% |
| 2012 | 116.54 Million SEK | -43.36% |
| 2011 | 205.75 Million SEK | 49.07% |
| 2010 | 138.03 Million SEK | 9.33% |
| 2009 | 126.24 Million SEK | -57.27% |
| 2008 | 295.42 Million SEK | 9.01% |
| 2007 | 271 Million SEK | 82.7% |
| 2006 | 148.33 Million SEK | -44.31% |
| 2005 | 266.34 Million SEK | 11.72% |
| 2004 | 238.4 Million SEK | -30.53% |
| 2003 | 343.18 Million SEK | -23.12% |
| 2002 | 446.4 Million SEK | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 1.19 Billion SEK | -9.76% |
| 2024 Q1 | 1.32 Billion SEK | -5.11% |
| 2024 Q3 | 1.08 Billion SEK | -9.3% |
| 2023 Q4 | 1.4 Billion SEK | -5.59% |
| 2023 Q3 | 1.48 Billion SEK | -7.24% |
| 2023 FY | 1.4 Billion SEK | -18.22% |
| 2023 Q2 | 1.59 Billion SEK | -3.48% |
| 2023 Q1 | 1.65 Billion SEK | -3.26% |
| 2022 Q1 | 1.38 Billion SEK | -4.6% |
| 2022 Q3 | 1.75 Billion SEK | 12.74% |
| 2022 Q4 | 1.71 Billion SEK | -2.44% |
| 2022 FY | 1.71 Billion SEK | 18.3% |
| 2022 Q2 | 1.55 Billion SEK | 12.75% |
| 2021 Q4 | 1.44 Billion SEK | -4.79% |
| 2021 FY | 1.44 Billion SEK | 80.32% |
| 2021 Q1 | 1.62 Billion SEK | 102.65% |
| 2021 Q3 | 1.52 Billion SEK | -4.28% |
| 2021 Q2 | 1.58 Billion SEK | -2.36% |
| 2020 Q1 | 194.33 Million SEK | -14.05% |
| 2020 FY | 802.64 Million SEK | 254.98% |
| 2020 Q4 | 802.64 Million SEK | 14.09% |
| 2020 Q3 | 703.53 Million SEK | 180.5% |
| 2020 Q2 | 250.82 Million SEK | 29.06% |
| 2019 Q3 | 273.79 Million SEK | -13.53% |
| 2019 Q4 | 226.11 Million SEK | -17.42% |
| 2019 FY | 226.11 Million SEK | 87.8% |
| 2019 Q1 | 141.22 Million SEK | 17.29% |
| 2019 Q2 | 316.63 Million SEK | 124.21% |
| 2018 Q1 | 227.21 Million SEK | 33.62% |
| 2018 FY | 120.4 Million SEK | -29.2% |
| 2018 Q2 | 184.57 Million SEK | -18.77% |
| 2018 Q4 | 120.4 Million SEK | -16.85% |
| 2018 Q3 | 144.79 Million SEK | -21.55% |
| 2017 Q4 | 170.04 Million SEK | -12.32% |
| 2017 FY | 170.04 Million SEK | -38.46% |
| 2017 Q1 | 238.37 Million SEK | -13.73% |
| 2017 Q2 | 220.19 Million SEK | -7.63% |
| 2017 Q3 | 193.93 Million SEK | -11.93% |
| 2016 FY | 276.29 Million SEK | 407.46% |
| 2016 Q3 | 217.29 Million SEK | -10.58% |
| 2016 Q2 | 243 Million SEK | 318.34% |
| 2016 Q1 | 58.08 Million SEK | 6.69% |
| 2016 Q4 | 276.29 Million SEK | 27.15% |
| 2015 Q1 | 49.35 Million SEK | -33.41% |
| 2015 Q4 | 54.44 Million SEK | -21.31% |
| 2015 Q3 | 69.19 Million SEK | -24.25% |
| 2015 Q2 | 91.33 Million SEK | 85.08% |
| 2015 FY | 54.44 Million SEK | -26.53% |
| 2014 Q4 | 74.1 Million SEK | -26.51% |
| 2014 FY | 74.1 Million SEK | -9.0% |
| 2014 Q3 | 100.83 Million SEK | -15.44% |
| 2014 Q2 | 119.25 Million SEK | 119.87% |
| 2014 Q1 | 54.23 Million SEK | -33.4% |
| 2013 FY | 81.43 Million SEK | -30.12% |
| 2013 Q2 | 57.73 Million SEK | -35.42% |
| 2013 Q3 | 55.63 Million SEK | -3.63% |
| 2013 Q1 | 89.4 Million SEK | -23.29% |
| 2013 Q4 | 81.43 Million SEK | 46.37% |
| 2012 FY | 116.54 Million SEK | -43.36% |
| 2012 Q1 | 161.83 Million SEK | -21.35% |
| 2012 Q2 | 212.89 Million SEK | 31.55% |
| 2012 Q3 | 180.78 Million SEK | -15.08% |
| 2012 Q4 | 116.54 Million SEK | -35.53% |
| 2011 Q1 | 190.56 Million SEK | 38.06% |
| 2011 Q2 | 280.62 Million SEK | 47.26% |
| 2011 Q3 | 240.16 Million SEK | -14.42% |
| 2011 Q4 | 205.75 Million SEK | -14.33% |
| 2011 FY | 205.75 Million SEK | 49.07% |
| 2010 Q1 | 221.37 Million SEK | 75.35% |
| 2010 FY | 138.03 Million SEK | 9.33% |
| 2010 Q3 | 182.93 Million SEK | -15.17% |
| 2010 Q2 | 215.64 Million SEK | -2.58% |
| 2010 Q4 | 138.03 Million SEK | -24.55% |
| 2009 Q4 | 126.24 Million SEK | 0.0% |
| 2009 FY | 126.24 Million SEK | -57.27% |
| 2008 FY | 295.42 Million SEK | 9.01% |
| 2007 FY | 271 Million SEK | 82.7% |
| 2006 FY | 148.33 Million SEK | -44.31% |
| 2005 FY | 266.34 Million SEK | 11.72% |
| 2004 FY | 238.4 Million SEK | -30.53% |
| 2003 FY | 343.18 Million SEK | -23.12% |
| 2002 FY | 446.4 Million SEK | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 118.45 Million SEK | -1082.085% |
| Ziccum AB (publ) | 14.97 Million SEK | -9251.99% |
| Modus Therapeutics Holding AB (publ) | 20.04 Million SEK | -6886.578% |
| BioArctic AB (publ) | 1.18 Billion SEK | -18.051% |
| Sprint Bioscience AB (publ) | 62.37 Million SEK | -2144.706% |
| Mendus AB (publ) | 755.95 Million SEK | -85.221% |
| Genovis AB (publ.) | 288.85 Million SEK | -384.731% |
| Intervacc AB (publ) | 259.61 Million SEK | -439.338% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 41.95 Million SEK | -3237.019% |
| Active Biotech AB (publ) | 44 Million SEK | -3082.227% |
| Magle Chemoswed Holding AB (publ) | 278.74 Million SEK | -402.316% |
| Bio-Works Technologies AB (publ) | 62.15 Million SEK | -2152.832% |
| Aptahem AB (publ) | 63.02 Million SEK | -2121.628% |
| Vicore Pharma Holding AB (publ) | 496.24 Million SEK | -182.153% |
| Kancera AB (publ) | 65.64 Million SEK | -2033.023% |
| Infant Bacterial Therapeutics AB (publ) | 351.33 Million SEK | -298.532% |
| Fluicell AB (publ) | 9.34 Million SEK | -14891.221% |
| Saniona AB (publ) | 64.14 Million SEK | -2082.904% |
| Lipigon Pharmaceuticals AB (publ) | 33.6 Million SEK | -4066.954% |
| Biovica International AB (publ) | 131.4 Million SEK | -965.521% |
| Spago Nanomedical AB (publ) | 52.98 Million SEK | -2542.597% |
| AcouSort AB (publ) | 34.51 Million SEK | -3956.964% |
| Xintela AB (publ) | 18.39 Million SEK | -7511.742% |
| Abliva AB (publ) | 87.49 Million SEK | -1500.224% |
| Egetis Therapeutics AB (publ) | 760.2 Million SEK | -84.186% |
| Karolinska Development AB (publ) | 1.25 Billion SEK | -11.267% |
| OncoZenge AB (publ) | 20.34 Million SEK | -6783.874% |
| Amniotics AB (publ) | 26.08 Million SEK | -5267.553% |
| 2cureX AB (publ) | 16.62 Million SEK | -8322.135% |
| CombiGene AB (publ) | 120.61 Million SEK | -1060.896% |
| Asarina Pharma AB (publ) | 6.07 Million SEK | -22940.645% |
| Calliditas Therapeutics AB (publ) | 1.9 Billion SEK | 26.328% |
| Camurus AB (publ) | 1.9 Billion SEK | 26.608% |
| Corline Biomedical AB | 100.1 Million SEK | -1298.711% |
| IRLAB Therapeutics AB (publ) | 177.12 Million SEK | -690.522% |
| Isofol Medical AB (publ) | 140.59 Million SEK | -895.882% |
| I-Tech AB | 152.44 Million SEK | -818.494% |
| Hansa Biopharma AB (publ) | 1.01 Billion SEK | -37.537% |
| Cyxone AB (publ) | 43.65 Million SEK | -3107.376% |
| ExpreS2ion Biotech Holding AB (publ) | 78.69 Million SEK | -1679.317% |
| Biosergen AB | 7.2 Million SEK | -19344.244% |
| Cantargia AB (publ) | 223.71 Million SEK | -525.885% |
| NextCell Pharma AB | 81.28 Million SEK | -1622.493% |
| Xspray Pharma AB (publ) | 765.26 Million SEK | -82.967% |
| Elicera Therapeutics AB (publ) | 30.17 Million SEK | -4540.501% |
| Nanologica AB (publ) | 77.42 Million SEK | -1708.341% |
| SynAct Pharma AB | 228.01 Million SEK | -514.063% |
| Annexin Pharmaceuticals AB (publ) | 26.76 Million SEK | -5131.775% |
| Stayble Therapeutics AB (publ) | 21.7 Million SEK | -6351.587% |
| LIDDS AB (publ) | 17.65 Million SEK | -7830.784% |
| Lipum AB (publ) | 12.11 Million SEK | -11462.18% |
| Alzinova AB (publ) | 123.18 Million SEK | -1036.611% |
| Oncopeptides AB (publ) | 238.37 Million SEK | -487.378% |
| Pila Pharma AB (publ) | 8.45 Million SEK | -16460.378% |
| Guard Therapeutics International AB (publ) | 85.22 Million SEK | -1542.883% |
| Scandinavian ChemoTech AB (publ) | 14.86 Million SEK | -9316.773% |
| Simris Alg AB (publ) | 174.55 Million SEK | -702.156% |
| Diamyd Medical AB (publ) | 217.03 Million SEK | -545.131% |
| Xbrane Biopharma AB (publ) | 653.5 Million SEK | -114.256% |
| Ascelia Pharma AB (publ) | 87.07 Million SEK | -1508.071% |
| Diagonal Bio AB (publ) | 28.5 Million SEK | -4811.534% |